Beijing Luzhu Biotechnology Co (HKSE:02480) Total Current Assets : HK$504.88 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Beijing Luzhu Biotechnology Co's total current assets for the quarter that ended in Dec. 2024 was HK$504.88 Mil.

Beijing Luzhu Biotechnology Co Total Current Assets Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Total Current Assets Chart

Beijing Luzhu Biotechnology Co Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Current Assets

703.20

671.15

679.21

504.88

Beijing Luzhu Biotechnology Co Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial			671.15	827.20	679.21	608.63	504.88

Beijing Luzhu Biotechnology Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Beijing Luzhu Biotechnology Co's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	484.381	+	1.287	+	6.123	+	13.085
	=	504.88

Beijing Luzhu Biotechnology Co's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	484.381	+	1.287	+	6.123	+	13.085
	=	504.88

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Beijing Luzhu Biotechnology Co (HKSE:02480) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Beijing Luzhu Biotechnology Co's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	484.381	-	210.195	+	0.75 * 0	+	0.5 * 6.123
=	277.25

Beijing Luzhu Biotechnology Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN

Website

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is its Core Product.

Executives

Kong Jian	2101 Beneficial owner
Zhang Yanping	2202 Interest of your spouse
Ma Jianan	2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo	2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo	2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
China Construction Bank Corporation	2201 Interest of corporation controlled by you
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Peng Ling	2201 Interest of corporation controlled by you
Ma Biao	2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co Headlines

No Headlines